新辅助卡多尼利马布加FLOT治疗晚期胃癌的疗效预测:基于身体组成变化的研究
Penghui Liu1, Na Li1, Jizhen Wang2
1Lanzhou University Second Clinical Medical College, Lanzhou, China.
Frontiers in oncology
|September 4, 2025
概括
在接受新辅助卡多尼利马布和FLOT治疗的晚期胃癌患者中,包括骨肌肉和内脏脂肪在内的身体组成变化可以预测治疗反应. 骨肌肉损失是治疗有效性的关键指标.
科学领域:
- 癌症学
- 胃肠病学
- 身体组成分析
背景情况:
- 晚期胃癌 (AGC) 面临重大治疗挑战.
- 结合免疫治疗的新辅助化疗是一种有前途的治疗方法.
- 个性化治疗策略对于优化患者的治疗结果至关重要.
研究的目的:
- 为了研究新辅助性卡多尼利马布加FLOT治疗对AGC的身体组成变化的预测价值.
- 确定与治疗疗效相关的特定体质参数.
- 提供针对晚期胃癌个性化治疗的见解.
主要方法:
- 对33名接受新辅助卡多尼利马布和FLOT治疗的AGC患者进行了回顾性分析.
- 在新辅助治疗之前和之后,使用InBody 720设备评估身体组成.
- 患者被分为客观反应和无进展组进行比较分析.
主要成果:
- 在应答组之间观察到瘦体质 (LBM),骨肌量 (SLM),骨肌量 (SMM),内脏脂肪面积 (VFA) 和阻抗的显著差异 (P < 0. 05).
- 下降的LBM,SLM和SMM与更好的治疗反应有关,在没有进展的组中减少更大.
- 在客观反应组中,VFA显著下降,而阻抗则增加.
- 干部和四肢SLM变化在没有进展的组中显示出更大的减少,表明干部SLM具有最显著的影响.
结论:
- 在LBM,SLM,SMM,VFA和阻抗的变化是新辅助剂cadonilimab加FLOT治疗疗效的有价值预测指标.
- LBM,SLM和SMM具有最高的预测值.
- 身体组成分析,特别是骨肌肉变异,可以指导晚期胃癌的个性化治疗策略.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880